Abstract:Ling Tong, 1, 2, &ast Xiangling Yu, 1, &ast Shan Wang, 1, 2 Ling Chen, 2 Yibo Wu 1 1 Human Reproductive and Genetic Center, Affiliated Hospital of Jiangnan University, Wuxi, People's Republic of China; 2 Department of Breast Surgery, Affiliated Hospital of Jiangnan University, Wuxi, People's Republic of China &astThese authors contributed equally to this work Correspondence: Ling Chen, Department of Breast Surgery, Affiliated Hospital of Jiangnan University, Wuxi, 214062, People's Republic of China, Email Yibo Wu, Human Reproductive and Genetic Center, Affiliated Hospital of Jiangnan University, Wuxi, 214062, People's Republic of China, Email Breast cancer has become the most common malignant tumor worldwide. Triple-negative breast cancer (TNBC) is a type of breast cancer that is negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Compared with other molecular subtypes of breast cancer, TNBC is the most aggressive and highly heterogeneous. TNBC is insensitive to endocrine and anti-HER2 therapy, and chemotherapy is currently the main systemic treatment. With the continuous development of detection techniques and deepening research on TNBC molecular subtypes, drugs targeting immune checkpoints and different targets have emerged, such as atezolizumab, pembrolizumab, poly (ADP-ribose) polymerase (PARP) inhibitors, trophoblast cell-surface antigen 2 (TROP-2), and antibody-drug conjugates. These therapies provide new hope for TNBC treatment. Based on the analysis and classification of TNBC, this article summarizes the immunotherapy, targeted therapy, and new treatment combinations, providing references for the precise treatment of TNBC in the future. Keywords: triple-negative breast cancer, immunotherapy, targeted therapy, precision therapy Breast cancer is currently the most common malignant tumor in women worldwide. According to data from the International Agency for Research on Cancer, there were 2.1 million new cases of breast cancer and nearly 700,000 deaths due to breast cancer globally in 2020. 1 Breast cancer can be classified into hormonal receptor-positive (HR), HER2-positive, and triple-negative breast cancer (TNBC) based on molecular markers. TNBC, which accounts for 15–20% of all breast cancers, is a type of malignant tumor with a poor prognosis. It is characterized by negative expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2), and its high degree of biological heterogeneity and invasiveness, make it the most aggressive and heterogeneous type of breast cancer. 2,3 Due to its unique biological behavior, it is insensitive to endocrine therapy and traditional HER2-targeted therapy, and chemotherapy is still considered the main systemic treatment for TNBC. However, there is a significant portion of patients who develop resistance to chemotherapy in clinical practice. 4 Therefore, identifying therapeutic targets (Such as EGFR, P13k/AKT/Mtor pathway, etc.) and more effective treatment modalities for TNBC is a clinical challenge and priority that needs to be urgently addressed. With the vigorous development of bioinformatics analysis technology and omics research, cancer research is gradually developing in the direction of multi-omics and refinement. In recent years, a variety of potential therapeutic targets have been discovered from the aspects of genomics, metabolomics, and proteomics, and many of the research results have certain clinical transformation value. Therefore, it is a future research direction to formulate corresponding treatment plans according to the unique and complex molecular characteristics of tumors of each patient, to achieve precise treatment of diseases, and to improve treatment efficacy and survival outcomes. This article will summarize the new progress in the treatment of TNBC, and provide a basis for establishing a precise treatment plan for TNBC in the future. TNBC is not a singular tumor but a highly heterogeneous mixed-type tumor, with significant differences in tumor biology and drug sensitivity among different patients. With the development of detection technologies, researchers can analyze the biological characteristics of tumors from multiple dimensions such as gene sequences, protein expression, and metabolism. By identifying specific biological features, they can discover crucial therapeutic targets. Therefore, identifying the molecular subtyping of TNBC will provide a foundation for further finding critical therapeutic targets, developing targeted drugs, and establishing precise treatment strategies. Based on different molecular features, multiple methods have been devel -Abstract Truncated-

Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer

Reassessment of Reliability and Reproducibility for Triple-Negative Breast Cancer Subtyping

The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification

Subclassifying triple-negative breast cancers and its potential clinical utility

Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance

Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies

Heterogeneity and potential therapeutic insights for triple-negative breast cancer based on metabolic‐associated molecular subtypes and genomic mutations

Stability and variability of molecular subtypes: comparative analysis of primary and metastatic triple-negative breast cancer

Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes

Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer

Molecular Subtypes and Precision Treatment of Triple-Negative Breast Cancer

Inflammatory Response-Based Subtyping and Potential Therapeutic Strategies for Triple-Negative Breast Cancer

Integrative Analysis of Metabolic Subtypes in Triple-Negative Breast Cancer Reveals New Therapeutic Strategies

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Triple-negative breast cancer molecular subtyping and treatment progress

Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection

Comprehensive Transcriptome Analysis Identifies Novel Molecular Subtypes And Subtype-Specific Incrnas Of Triple-Negative Breast Cancer

A senescence-associated signature refines the classification of different modification patterns and characterization of tumor immune microenvironment infiltration in triple-negative breast cancer.

Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer

The treatment landscape of triple-negative breast cancer